Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Stigma strong against lung cancer patients

06 Nov 2019
Lung cancer patients suffer from stigma, which compromises their self-esteem and self-efficacy, according to a recent China study.

Researchers enrolled 283 lung cancer patients (mean age, 52.98±11.08 years; 61.5 percent male) who were asked to complete questionnaires that collected, among other things, demographic variables, disease disclosure, negative changes in body image or family relationships, and perceived blame. The social impact scale (SIS) was used to measure lung cancer stigma.

More than a third (39.6 percent) of the participants hid their diagnosis from others, while almost all reported negative changes in economic burden (91.5 percent) and body image (90.8 percent). Almost a quarter (23.7 percent) reported perceived blame. The mean SIS score was 2.38±0.45, indicating moderate stigma.

Stigma was significantly and negatively correlated with patient self-esteem (r, –0.607; p<0.001) and coping self-efficacy (r, –0.424; p<0.001).

Multiple linear regression analysis confirmed that elevated levels of stigma were significantly associated with poor self-esteem (adjusted r2, 0.367; p<0.001) and coping self-efficacy (adjusted r2, 0.470; p=0.028).

Other significant correlates of stigma included younger age (adjusted r2, 0.476; p=0.037), higher cancer stage (adjusted r2, 0.463; p=0.019), perceived blame (adjusted r2, 0.436; p=0.002), concealment of diagnosis (adjusted r2, 0.455; p=0.01), and greater negative impacts on financial burden (adjusted r2, 0.420; p=0.001), body image (adjusted r2, 0.446; p=0.051) and family relationship (adjusted r2, 0.482; p=0.049).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.